These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9228064)

  • 1. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.
    Coleman KG; Wautlet BS; Morrissey D; Mulheron J; Sedman SA; Brinkley P; Price S; Webster KR
    J Biol Chem; 1997 Jul; 272(30):18869-74. PubMed ID: 9228064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
    Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.
    Ragione FD; Russo GL; Oliva A; Mercurio C; Mastropietro S; Pietra VD; Zappia V
    J Biol Chem; 1996 Jul; 271(27):15942-9. PubMed ID: 8663131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
    Serrano M; Hannon GJ; Beach D
    Nature; 1993 Dec; 366(6456):704-7. PubMed ID: 8259215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.
    Zhao Q; Boschelli F; Caplan AJ; Arndt KT
    J Biol Chem; 2004 Mar; 279(13):12560-4. PubMed ID: 14701845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of p16INK4a and its interaction with CDK4.
    Yang R; Serrano M; Slater J; Leung E; Koeffler HP
    Biochem Biophys Res Commun; 1996 Jan; 218(1):254-9. PubMed ID: 8573142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
    Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
    Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between Cdc37 and Cdk4 in human cells.
    Lamphere L; Fiore F; Xu X; Brizuela L; Keezer S; Sardet C; Draetta GF; Gyuris J
    Oncogene; 1997 Apr; 14(16):1999-2004. PubMed ID: 9150368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
    Phelps DE; Xiong Y
    Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.
    Parry D; Bates S; Mann DJ; Peters G
    EMBO J; 1995 Feb; 14(3):503-11. PubMed ID: 7859739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct binding of the N-terminus of HTLV-1 tax oncoprotein to cyclin-dependent kinase 4 is a dominant path to stimulate the kinase activity.
    Li J; Li H; Tsai MD
    Biochemistry; 2003 Jun; 42(22):6921-8. PubMed ID: 12779347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nuclear protein p34SEI-1 regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner.
    Li J; Melvin WS; Tsai MD; Muscarella P
    Biochemistry; 2004 Apr; 43(14):4394-9. PubMed ID: 15065884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical characterizations reveal different properties between CDK4/cyclin D1 and CDK2/cyclin A.
    Kim DM; Yang K; Yang BS
    Exp Mol Med; 2003 Oct; 35(5):421-30. PubMed ID: 14646596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
    Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
    J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4.
    Said TK; Luo L; Medina D
    Carcinogenesis; 1995 Oct; 16(10):2507-13. PubMed ID: 7586159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
    Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.
    Maelandsmo GM; Flørenes VA; Hovig E; Oyjord T; Engebraaten O; Holm R; Børresen AL; Fodstad O
    Br J Cancer; 1996 Apr; 73(8):909-16. PubMed ID: 8611425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.